Asploro Journal of Biomedical and Clinical Case Reports

Asploro Journal of Biomedical and Clinical Case Reports

Yi Yang¹, Yiding Zuo², Li Zhou^2*
1Department of Anesthesiology, ChengDu Shangjin Nanfu Hospital, Sichuan, China
²Department of Anesthesiology, West China Hospital of Sichuan University, Sichuan, China

Corresponding Author: Li Zhou ^{ORCID iD}
Address: Department of Anesthesiology, West China Hospital of Sichuan University, Sichuan, China.
Received date: 16 July 2022; Accepted date: 01 August 2022; Published date: 08 August 2022

Citation: Yang Y, Zuo Y, Zhou L. The Mechanism of Propofol on Non-Small Cell Lung Cancer (NSCLC) through Modulating Mesenchymal Transition (EMT). Asp Biomed Clin Case Rep. 2022 Aug 08;5(2):94-104.

Copyright © 2022 Yang Y, Zuo Y, Zhou L. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Propofol, Cancer Stem-Like Cells (CSCS), Non-Small Cell Lung Cancer, Mesenchymal Transition, Self-Renewal Capacity

Abstract

Background: Intensive investigations have focused on the effect of propofol on the malignant behaviours of cancer cells. However, much is still unknown about the effect of propofol on non-small cell lung cancer (NSCLC). Here we aimed to investigate the effect of propofol on NSCLC with cancer stem-like cells (CSCs) A549.
Methods: CCK-8 assays, flow cytometry, and transwell assay were used to assess the changes in the proliferation, migration, and invasion in A549 treated with propofol. By detecting hallmarks of mesenchymal transition (EMT), the mechanism of the effect of propofol on A549 was assessed.
Results: In A549, propofol exposure promoted cell proliferation, while inhibiting migration and invasion. By activating EMT using TGF-β pretreatment, propofol treatment downregulated hallmarks of EMT and led to inactivation of EMT.
Conclusion: Modulation of self-renewal capacity of CSCs by anesthetics may affect cancer malignant behaviors following surgery. The employment of propofol not only exerts inhibitory effects on cancer cells but also on CSCs in non-small cell lung cancer.